Massimo L’Andolina
YOU?
Author Swipe
View article: Real-Life Use of Filgotinib in Rheumatoid Arthritis: A Retrospective Cohort Study
Real-Life Use of Filgotinib in Rheumatoid Arthritis: A Retrospective Cohort Study Open
Background: Janus kinase inhibitors (JAKis) are a novel class of drugs interfering with intracellular signaling of type I and type II cytokines, which play a crucial role in immune dysregulation associated with several chronic inflammatory…
View article: Real-Life Use of Filgotinib in Rheumatoid arthritis:A Retrospective Cohort Study
Real-Life Use of Filgotinib in Rheumatoid arthritis:A Retrospective Cohort Study Open
Background: In the aftermath of the ORAL Surveillance trial, real-world studies are needed to elucidate the effectiveness and safety of Janus kinase inhibitors (JAKis) in routine clinical practice. Methods: We performed a multicenter, retr…
View article: Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase Open
View article: Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in theFirst Three Pandemic Waves. Relationship with Disease Subgroups and OngoingTherapies
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in theFirst Three Pandemic Waves. Relationship with Disease Subgroups and OngoingTherapies Open
Objective: Autoimmune systemic diseases (ASD) represent a predisposing condition to COVID-19. Our prospective, observational multicenter telephone survey study aimed to investigate the prevalence, prognostic factors, and outcomes of COVID-…
View article: Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups Open
View article: Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments Open
Background: The Covid-19 pandemic may have a deleterious impact on patients with autoimmune systemic diseases (ASD) due to their deep immune-system alterations. Objective: This study aims to investigate the prevalence of symptomatic Covid-…
View article: COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study Open
View article: Impaired Immunogenicity to COVID-19 Vaccines in Autoimmune Systemic Diseases - High Prevalence of Non-Response in Different Patients’ Subgroups
Impaired Immunogenicity to COVID-19 Vaccines in Autoimmune Systemic Diseases - High Prevalence of Non-Response in Different Patients’ Subgroups Open
View article: COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series Open
View article: Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP)
Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP) Open
In conclusion, our study provides further evidence of a critical role of active pharmacovigilance in detection, reporting and analysis of AEs in rheumatology.